Stocks Health care VRCA
NASDAQ · Health careVerrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. brought in $30.3M of revenue over the twelve months to June 30, 2026, up 106.2% from a year earlier. It posted a net loss of $31.2M. In fiscal 2025 capital spending exceeded operating cash flow by $17.6M. At June 30, 2026 it held $11.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Verrica Pharmaceuticals Inc. does
Verrica Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VRCA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $35.6M | -$17.9M | -$1.68 | -$17.6M |
| 2024 | $7.6M | -$76.6M | -$14.78 | -$61M |
| 2023 | $5.1M | -$67M | -$14.78 | -$38.9M |
| 2022 | $9M | -$24.5M | -$7.19 | -$19M |
| 2021 | $12M | -$35.1M | -$12.98 | -$28.5M |
| 2020 | n/a | -$42.7M | -$17.08 | -$31.7M |
Latest SEC filings
What Verrica Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 9, 2026
- May 12, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026
- May 12, 2026
- April 20, 2026
- April 20, 2026Additional proxy material DEFA14A
- April 20, 2026Proxy statement DEF 14A
- March 11, 2026Annual report 10-K · period to December 31, 2025
Questions about VRCA
What does Verrica Pharmaceuticals Inc. do?
Verrica Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VRCA.
Is Verrica Pharmaceuticals Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $31.2M on revenue of $30.3M.
How much revenue does Verrica Pharmaceuticals Inc. make?
Over the twelve months to June 30, 2026 Verrica Pharmaceuticals Inc. reported revenue of $30.3M. That is 106.2% more than a year earlier.
When did Verrica Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 18, 2026.
Similar companies
Follow VRCA
Get an email when Verrica Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow VRCA: get an email when it filesWhere the numbers come from
Financial figures are the values Verrica Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.